CRISPR Therapeutics AG
CRSP63.990USD
+2.890+4.73%
收盘 10/31, 16:00（美东）报价延迟15分钟
5.66B总市值
亏损市盈率 TTM
关于 CRISPR Therapeutics AG 公司
CRISPR Therapeutics AG 是一家总部位于瑞士的基因编辑公司，专注于开发基于 CRISPR/Cas9 的疗法。CRISPR/Cas9 代表成簇的规律间隔短回文重复序列 (CRISPR)/CRISPR 相关蛋白 9 (Cas9)，是一种基因编辑技术，即精确改变基因组 DNA 特定序列的过程。该公司旨在应用这项技术来破坏、删除、纠正和插入基因，以治疗基因定义的疾病并设计先进的细胞疗法。该公司已获得涵盖 CRISPR/Cas9 和相关技术的知识产权 (IP) 的权利，并且还参与了自己的知识产权研究和其他许可工作。公司的产品开发和合作战略旨在充分利用 CRISPR/Cas9 平台的潜力，同时最大限度地提高成功开发其候选产品的可能性。
CRISPR Therapeutics AG简介
公司代码CRSP
公司名称CRISPR Therapeutics AG
上市日期Oct 19, 2016
CEODr. Samarth Kulkarni, Ph.D.
员工数量393
证券类型Ordinary Share
年结日Oct 19
公司地址Baarerstrasse 14
城市ZUG
上市交易所NASDAQ Global Market Consolidated
国家Switzerland
邮编6300
电话41415613279
网址https://crisprtx.com/
公司代码CRSP
上市日期Oct 19, 2016
CEODr. Samarth Kulkarni, Ph.D.
CRISPR Therapeutics AG公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
339.82K
+18.56%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Sandesh Mahatme
Mr. Sandesh Mahatme
Independent Director
Independent Director
--
--
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Fardis, Ph.D.
Dr. Maria Fardis, Ph.D.
Independent Director
Independent Director
--
--
Dr. H. Edward Fleming, Jr., M.D.
Dr. H. Edward Fleming, Jr., M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
339.82K
+18.56%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 10月26日 周日
更新时间: 10月26日 周日
持股股东
股东类型
持股股东
持股股东
占比
ARK Investment Management LLC
11.20%
Capital International Investors
6.15%
BlackRock Institutional Trust Company, N.A.
5.96%
T. Rowe Price Investment Management, Inc.
4.05%
State Street Investment Management (US)
3.60%
其他
69.05%
持股股东
持股股东
占比
ARK Investment Management LLC
11.20%
Capital International Investors
6.15%
BlackRock Institutional Trust Company, N.A.
5.96%
T. Rowe Price Investment Management, Inc.
4.05%
State Street Investment Management (US)
3.60%
其他
69.05%
股东类型
持股股东
占比
Investment Advisor
46.56%
Investment Advisor/Hedge Fund
21.44%
Hedge Fund
3.78%
Venture Capital
3.45%
Research Firm
3.18%
Individual Investor
1.69%
Bank and Trust
1.57%
Pension Fund
0.46%
Sovereign Wealth Fund
0.45%
其他
17.43%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
966
73.70M
81.03%
+1.45M
2025Q2
949
75.06M
82.87%
+271.52K
2025Q1
952
68.11M
78.87%
-5.61M
2024Q4
955
68.20M
79.52%
-1.17M
2024Q3
962
64.14M
75.29%
-1.47M
2024Q2
976
63.22M
74.44%
-1.89M
2024Q1
986
62.72M
74.09%
+4.47M
2023Q4
985
55.14M
69.41%
-4.96M
2023Q3
992
55.19M
69.50%
-6.68M
2023Q2
1037
54.86M
69.51%
-8.28M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
ARK Investment Management LLC
10.18M
11.2%
+17.19K
+0.17%
Jun 30, 2025
Capital International Investors
5.59M
6.15%
-479.37K
-7.89%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.42M
5.96%
+3.00M
+124.40%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
3.68M
4.05%
-115.08K
-3.03%
Jun 30, 2025
State Street Investment Management (US)
3.27M
3.6%
+859.33K
+35.64%
Jun 30, 2025
Two Sigma Investments, LP
2.89M
3.18%
+904.31K
+45.53%
Jun 30, 2025
Orbis Investment Management Ltd.
2.76M
3.04%
+1.20M
+76.88%
Jun 30, 2025
UBS Financial Services, Inc.
2.59M
2.85%
+859.43K
+49.73%
Jun 30, 2025
Amova Asset Management Americas, Inc
2.41M
2.65%
-125.62K
-4.95%
Jun 30, 2025
The Vanguard Group, Inc.
2.28M
2.51%
+528.38K
+30.18%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月6日 周一
更新时间: 10月6日 周一
机构名称
占比
ARK Genomic Revolution ETF
9.22%
Global X Genomics & Biotechnology ETF
4.9%
ARK Innovation ETF
4.71%
AXS Green Alpha ETF
4.09%
WisdomTree BioRevolution Fund
2.74%
Virtus LifeSci Biotech Products ETF
2.09%
ROBO Global Healthcare Technology & Innovation ETF
2.01%
SPDR S&P Biotech ETF
1.44%
Direxion Daily S&P Biotech Bull 3X Shares
0.87%
Franklin Genomic Advancements ETF
0.77%
查看更多
ARK Genomic Revolution ETF
占比9.22%
Global X Genomics & Biotechnology ETF
占比4.9%
ARK Innovation ETF
占比4.71%
AXS Green Alpha ETF
占比4.09%
WisdomTree BioRevolution Fund
占比2.74%
Virtus LifeSci Biotech Products ETF
占比2.09%
ROBO Global Healthcare Technology & Innovation ETF
占比2.01%
SPDR S&P Biotech ETF
占比1.44%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.87%
Franklin Genomic Advancements ETF
占比0.77%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
